Shots:

• The US NIH to provide vaccine candidates and related material to Medigen Vaccine Biologic (MVC) to initiate the preclinical development of a vaccine for Covid-19 in Taiwan
• The results from a preclinical study will be used to assess the possibility of applying it to clinical testing on humans and developing a new generation of vaccines
• The collaboration marks the second collaboration b/w MVC and NIH since 2015- earlier collaborated to develop a vaccine against dengue fever. Additionally- on Feb 12- 2020- MVC has applied for permission to Taiwan FDA for its RT-PCR tests kit- developed to target corona virus

Click here ­to­ read full press release/ article | Ref: The Star | Image: Sequencing